

# VIRGINIA

## CHRONIC HEPATITIS<sup>1</sup>

**Male Liver Cancer Incidence Rates per 100,000 :** 11.1  
**Female Liver Cancer Incidence Rates per 100,000 :** 3.6  
**State Population:** 7,841,754  
**HCV in General Population:** 125,468  
**HCV in Baby Boomer Population:** 83,686  
**HCV in Caucasian:** 82,200  
**HCV in African American:** 45,963  
**HCV in API:** 11,180  
**HCV in Latino:** 7,474  
**HBV in General Population:** 31,367  
**HBV in African American:** 15,322  
**HBV in API:** 44,719  
**HBV in Latino:** 1,724  
**Adult Hepatitis Prevention Coordinator:** Rachel Culp  
**E-mail:** Rachel.culp@vdh.virginia.gov

## DRUG RELATED DEATHS<sup>2</sup>



## STATE OPIOID POLICIES<sup>2</sup>

Opioid Policy Provision	Status
Syringe Exchange Program Legality	Legal
Prescribers required to check a prescription drug monitoring program before prescribing controlled substances	Required
Jurisdictions submitted request for CDC Consultation demonstrating high risk of HCV or HIV outbreak due to drug use	State Completed

## STATE HCV MEDICAID POLICIES<sup>2</sup>

HCV Medicaid Policy Provision	Status
Liver damage restrictions	Fee-For Service (FFS) and Managed Care Organizations (MCOs) do not have liver damage restrictions
Sobriety restrictions	FFS and MCOs require beneficiaries to be evaluated for current substance or alcohol use. Those identified with alcohol or substance use should be referred for treatment. Prior authorization (PA) forms state explicitly that a patient can't be denied treatment for the sole reason of substance use.


Source:

1. Caring Ambassadors Program, [www.hepcchallenge.org](http://www.hepcchallenge.org)

2. amfAR, 2018;

Hepatitis C: State of Medicaid Access, 2017

## HEPATITIS C AND OPIOID INJECTION ROSE DRAMATICALLY IN YOUNGER AMERICANS FROM 2004-2014



- Among people aged 18-29, HCV increased by 400% and admission for opioid injection by 622%
- Among people aged 30-39, HCV increased by 325% and admission for opioid injection by 83%

— Any Opioid Injection (18-29)  
 — Any Opioid Injection (30-39)  
 - - - HCV Rate (18-29)  
 - - - HCV Rate (30-39)

Source: Centers for Disease Control and Prevention and Substance Abuse and Mental Health Services Administration

*“Hepatitis C is a deadly, common, and often invisible result of America’s opioid crisis,” said Jonathan Mermin, M.D., M.P.H., director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. “By testing people who inject drugs for hepatitis C infection, treating those who test positive, and preventing new transmissions, we can mitigate some of the effects of the nation’s devastating opioid crisis and save lives.”*

### Treatment and Prevention Services<sup>2</sup>

#

Syringe Exchange Programs

0


Facilities providing substance abuse services

194

Facilities providing some Medication Assisted Treatment (MAT)

96  
...of which 60 accept Medicaid

### CDC Vulnerable Counties



## HEALTHCARE ACCESS<sup>2</sup>

Healthcare Access	VA	US
Percent of People without Health Insurance	10.7	11.7
Percent Needing but Not Receiving Addiction Treatment	90.91	88.89
Number of 30 Days Supply of Opioids per Part D Enrollee	2.14	2.08
Opioids prescribed per capita, in morphine mg equivalents (MME)	585.05	642.05